Antibodies in Repeated Influenza Vaccination (ARIVA) Study

University Hospital Basel

Status: Completed

Conditions: Vaccine Response Impaired

Treatments: Biological: Influenza Vaccination

Study type: Observational

Funder types: Other

Identifiers

NCT04059991

ARIVA_me17Berger

Details and patient eligibility

About

Viruses with high mutation rates, such influenza or HIV, pose a major challenge for vaccine design. The current influenza vaccination strategy of yearly vaccination with adapted strains aims to maximally diversify the antibody immune response to prevent viral escape. There is, however, growing evidence, that repeated vaccination with very similar viral proteins might limit, instead of broaden, diversification and thereby reduce vaccine efficacy.

The ARIVA Study prospectively studies the immunological impact of repeated influenza vaccination on viral variant recognition and antibody responses in healthy subjects cross-sectionally and over three consecutive vaccination seasons.

Enrollment: 150 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• influenza vaccination (QIIV) independent of the study
• age >18 yo

Exclusion criteria

• no vaccination
• current acute illness